RESUMEN
In past studies conducted by our group, riparin I (rip I) isolated from the green fruit of Aniba riparia presented antianxiety effects in mice, while its analogs rip II and III showed anxiolytic and antidepressant-like actions. This time around, we investigated a possible antidepressant activity of rip I using the forced swimming test (FST) and tail suspension test (TST) as predictive tests for antidepressant activity in rodents. In addition, the involvement of the monoaminergic system in this effect was also assessed. rip I was acutely administered by intraperitoneal (i.p.) and oral (p.o) routes to male mice at doses of 25 and 50 mg/kg. Results showed that rip I at both tested doses and administration routes produced a significant decrease in immobility time in FST and TST. The pretreatment of mice with prazosin (1 mg/kg, i.p., an α1 -adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an α2 -adrenoceptor antagonist), SCH23390 (15 µg/kg, i.p., a dopamine D1 receptor antagonist), sulpiride (50 mg/kg, i.p., a dopamine D2 receptor antagonist), p-chlorophenylalanine (100 mg/kg, an inhibitor of serotonin synthesis) or ritanserin (4 mg/kg, a serotonin 5-HT2(A)/2(C) receptor antagonist) blocked the anti-immobility effects elicited by rip I (50 mg/kg, p.o.) in the FST. Taken together, results indicate that rip I produces significant antidepressant-like activity in the FST and TST, and this effect seems to be dependent on its interaction with noradrenergic, dopaminergic and serotonergic systems.
Asunto(s)
Antidepresivos/química , Antidepresivos/farmacología , Conducta Animal/efectos de los fármacos , Benzamidas/farmacología , Lauraceae/química , Tiramina/farmacología , Animales , Ansiolíticos/química , Ansiolíticos/farmacología , Dopamina/farmacología , Suspensión Trasera/métodos , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Norepinefrina/farmacología , Natación , Tiramina/análogos & derivadosRESUMEN
Riparin II (RipII), an alkamide isolated from the green fruit of Aniba riparia, was tested in the various animal models of inflammation to investigate its anti-inflammatory activity. Male Wistar rats (180-240g) were treated with RipII by gavage at doses 25 or 50mg/kg, before initiating the inflammatory responses. The tests used were paw edema induced by carrageenan, dextran, histamine or serotonin; peritonitis induced by carrageenan and fMLP, as well as the measurement of MPO activity, TNF-α and Il-1ß amount in the peritoneal fluid. In the animal models of carrageenan and dextran-induced paw edema, the animals treated with RipII showed lower edema than those of the control group. Treatment with RipII also reduced the paw edema induced by histamine but not serotonin. In the carrageenan-induced peritonitis model, treatment with RipII reduced leukocyte migration, the MPO activity and the amount of TNF-α and IL-1ß in the peritoneal fluid. In summary, these results indicate that RipII has an anti-inflammatory activity in chemical models of acute inflammation. RipII might be directly or indirectly inhibiting the activity, production or release of pro-inflammatory mediators involved in the generation of the pain associated with inflammation.
Asunto(s)
Antiinflamatorios/farmacología , Benzamidas/farmacología , Inflamación/tratamiento farmacológico , Tiramina/análogos & derivados , Animales , Modelos Animales de Enfermedad , Edema/inducido químicamente , Edema/tratamiento farmacológico , Inflamación/inducido químicamente , Masculino , Malondialdehído/metabolismo , Ratones , Peritonitis/inducido químicamente , Peritonitis/tratamiento farmacológico , Ratas , Ratas Wistar , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo , Tiramina/farmacologíaRESUMEN
In a previous study conducted by our group, riparin II (ripII) isolated from the green fruit of Aniba riparia presented antianxiety effects in mice. This study investigates a possible antidepressant activity of rip II using two predictive tests for antidepressant activity in rodents: the forced swimming test (FST) and tail suspension test (TST). Additionally, the mechanisms involved in the antidepressant-like effect in mice were also assessed. Rip II was acute administered by intraperitoneal (i.p.) and oral (p.o) routes to male mice at doses of 25 and 50 mg/kg. Results showed that ripII at both tested doses and administration routes produced a significant decrease of immobility time in FST and TST. The pretreatment of mice with prazosin (1 mg/kg, i.p., an α1-adrenoceptor antagonist), SCH23390 (15 µg/kg, i.p., a dopamine D1 receptor antagonist), sulpiride (50 mg/kg, i.p., a dopamine D2 receptor antagonist), p-chlorophenylalanine (100 mg/kg, an inhibitor of serotonin synthesis), or NAN-190 (0.5 mg/kg, a serotonin 5-HT1A receptor antagonist) completely blocked the anti-immobility effects elicited by riparin II (50 mg/kg, p.o.) in the FST. This study indicates that riparin II produces significant antidepressant-like activity in the forced swimming and TSTs, and this effect seems to be dependent on its interaction with noradrenergic, dopaminergic, and serotonergic systems.
Asunto(s)
Neuronas Adrenérgicas/efectos de los fármacos , Antidepresivos/farmacología , Benzamidas/farmacología , Dopaminérgicos/farmacología , Serotoninérgicos/farmacología , Tiramina/análogos & derivados , Animales , Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Frutas/química , Suspensión Trasera , Pérdida de Tono Postural/efectos de los fármacos , Lauraceae/química , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Natación , Tiramina/farmacologíaRESUMEN
Dehydrodieugenol, known as bis-eugenol, is a eugenol ortho dimer, and both compounds were able to exhibit anti-inflammatory and antioxidant activities in previous studies. Furthermore, eugenol showed antidepressant-like effect; however, the biological actions of bis-eugenol on experimental models for screening antidepressant activity are still unknown. The present study investigated a possible antidepressant-like activity of bis-eugenol in the forced swimming test (FST) and tail suspension test (TST) in mice and the involvement in the monoaminergic system in this effect. In addition, a neurochemical analysis on brain monoamines of mice acutely treated with bis-eugenol was also conducted. Bis-eugenol decreased the immobility time in the FST and TST without accompanying changes in ambulation in the open field test at 10 mg/kg, i.p.. Nevertheless, it induced ambulation at 25 and 50 mg/kg doses. The anti-immobility effect of bis-eugenol (10 and 50 mg/kg, i.p.) was prevented by pretreatment of mice with p-chlorophenylalanine (PCPA, 100 mg/kg, i.p., an inhibitor of serotonin synthesis, for four consecutive days), yohimbine (1 mg/kg, i.p., an α2-adrenoceptor antagonist), SCH23390 (15 µg/kg, s.c., a dopamine D1 receptor antagonist) and sulpiride (50 mg/kg, i.p., a dopamine D2 receptor antagonist). Monoamines analysis using high-performance liquid chromatograph revealed significant increase in the 5-HT, NE and DA levels in brain striatum. The present study indicates that bis-eugenol possesses antidepressant-like activity in FST and TST by altering dopaminergic, serotonergic and noradrenergic systems function.
Asunto(s)
Antidepresivos/uso terapéutico , Monoaminas Biogénicas/agonistas , Cuerpo Estriado/efectos de los fármacos , Depresión/tratamiento farmacológico , Modelos Animales de Enfermedad , Eugenol/análogos & derivados , Lignanos/uso terapéutico , Neuronas/efectos de los fármacos , Neuronas Adrenérgicas/efectos de los fármacos , Neuronas Adrenérgicas/metabolismo , Animales , Antidepresivos/administración & dosificación , Antidepresivos/efectos adversos , Antidepresivos/antagonistas & inhibidores , Conducta Animal/efectos de los fármacos , Monoaminas Biogénicas/metabolismo , Cuerpo Estriado/metabolismo , Depresión/metabolismo , Dopamina/química , Dopamina/metabolismo , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas Dopaminérgicas/metabolismo , Relación Dosis-Respuesta a Droga , Eugenol/administración & dosificación , Eugenol/efectos adversos , Eugenol/antagonistas & inhibidores , Eugenol/uso terapéutico , Conducta Exploratoria/efectos de los fármacos , Lignanos/administración & dosificación , Lignanos/efectos adversos , Lignanos/antagonistas & inhibidores , Masculino , Ratones , Neuronas/metabolismo , Norepinefrina/agonistas , Norepinefrina/metabolismo , Neuronas Serotoninérgicas/efectos de los fármacos , Neuronas Serotoninérgicas/metabolismo , Serotonina/química , Serotonina/metabolismo , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Cocaine is used worldwide and considered a public health problem. Relapse from addiction is one of the difficulties faced by cocaine users, and in most cases according to the period of abstinence, users may present symptoms such as anxiety or depression. To evaluate the anxiety-like behavior induced by different periods, rats were treated for 7 days with cocaine 20 mg/kg, i.p., and 24 h, 7 and 21 days after drug withdrawal were submitted to the elevated plus maze (EPM) and the open field (OF) tests. In different protocol, propranolol (10 mg/kg, i.p.), ondansetron (4 mg/kg, i.p.) and buspirone (5 mg/kg, i.p.) were administered once after 24 h and 7 days of abstinence from cocaine to evaluate possible reversal or attenuation of the symptoms caused by cocaine withdrawal. EPM results showed a reduction in all parameters after 24 h and 7 days of the last exposure to cocaine, indicating anxiety-like behavior. In the OF test, 24 h and 7 days of abstinence showed increased locomotor activity, while in the withdrawal 21 days the animals not alter the locomotor activity. The administration of propranolol, ondansetron or buspirone after a 24 h abstinence period reduced the animals anxiety in the EPM, and in the OF all drugs were able to reduce locomotor activity. After abstinence 7 d, the drugs reduced locomotor activity in the OF, in the EMP propranolol and ondansetron reversed the anxiogenic effect induced by cocaine. These results suggest that the treatment of anxyogenic effects of abstinence from cocaine is dependent on the period of the withdrawal.
Asunto(s)
Ansiolíticos/uso terapéutico , Ansiedad/tratamiento farmacológico , Conducta Animal/efectos de los fármacos , Cocaína/efectos adversos , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Animales , Ansiolíticos/farmacología , Ansiedad/inducido químicamente , Buspirona/farmacología , Buspirona/uso terapéutico , Masculino , Actividad Motora/efectos de los fármacos , Ondansetrón/farmacología , Ondansetrón/uso terapéutico , Propranolol/farmacología , Propranolol/uso terapéutico , Ratas , Ratas WistarRESUMEN
OBJECTIVES: The antipsychotic, hypnotic, myorelaxant and antioxidant effects of the essential oil of Alpinia zerumbet (EOAZ) were studied. METHODS: EOAZ (50, 100 and 200 mg/kg i.p.) was administered once to mice for the determination of antipsychotic activity (evaluated by ketamine-induced hyperlocomotion), hypnotic activity (induced by sodium pentobarbital, 40 mg/kg i.p.), motor coordination (rotarod test), antioxidant effects (determination of lipid peroxidation and GSH levels), as well as alterations in nitric oxide levels (determination of nitrite content). KEY FINDINGS: EOAZ at doses of 100 and 200 mg/kg prevented ketamine hyperlocomotion, as did haloperidol (0.2 mg/kg i.p). EOAZ at a dose of 200 mg/kg decreased sleep latency, while all doses increased sleeping time. There was no effect on motor coordination. The in-vitro antioxidant capacity of the oil caused a decrease in lipid peroxidation and increase in GSH levels. EOAZ also prevented the decrease in nitrite content caused by oxidative stress. CONCLUSIONS: The results suggest antipsychotic and antioxidant effects for the EOAZ that may have promising efficacy for the treatment of schizophrenia.
Asunto(s)
Alpinia/química , Antioxidantes/farmacología , Antipsicóticos/farmacología , Hipnóticos y Sedantes/farmacología , Locomoción/efectos de los fármacos , Aceites Volátiles/farmacología , Esquizofrenia/fisiopatología , Animales , Antioxidantes/uso terapéutico , Antipsicóticos/uso terapéutico , Glutatión/metabolismo , Haloperidol/farmacología , Haloperidol/uso terapéutico , Hipnóticos y Sedantes/uso terapéutico , Ketamina , Peroxidación de Lípido/efectos de los fármacos , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Nitritos/metabolismo , Aceites Volátiles/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/química , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Hojas de la Planta , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/metabolismo , Sueño/efectos de los fármacosRESUMEN
Recent studies have shown that some monoterpenes exert anxiolytic- and depressant-like actions, however, these effects from monoterpene 1,4-cineole are still unknown. This work aimed to study the effects of 1,4-cineole in classic animal models for depression- and anxiety-like behavior, specifically the elevated plus maze (EPM), hole board, open field, pentobarbital sleeping time, forced swimming, tail suspension and rota rod tests. 1,4-Cineole was administered orally to mice (100, 200 and 400 mg/kg), while diazepam (1 or 2 mg/kg) and imipramine (10 or 30 mg/kg) were used as standard drugs. 1,4-Cineole (400 mg/kg) modified all parameters observed in the EPM, while no significant variation was observed on general motor activity in the open-field test. In the hole-board assay, 1,4-cineole induced increase on the number of head dips. Forced swimming and tail suspension tests showed that cineole (200 and/or 400 mg/kg) was able to promote significant increase on the immobility time, while a decreased sleep latency was observed (200 and 400 mg/kg ) on the pentobarbital sleeping time. Cineole had no effect on the motor coordination of animals in the rota rod test. The results suggest that 1,4-cineole presents potential anxiolytic-like action consistent with possible general depression of the CNS.
Asunto(s)
Ansiolíticos/farmacología , Conducta Animal/efectos de los fármacos , Monoterpenos/farmacología , Animales , Monoterpenos Ciclohexánicos , RatonesRESUMEN
A growing body of evidence has pointed to the ionotropic glutamate N-methyl-d-aspartate receptor (NMDA) as an important player in the etiology of psychopathologies, including anxiety and major depression. Clinical findings suggest that ketamine may be used for the treatment of major depression. There is evidence that reactive oxygen species also play an important role in the pathogenesis of many diseases, particularly those which are neurological and psychiatric in nature. This study examined the behavioral and oxidative stress alterations after a single administration of ketamine (5, 10 and 20mg/kg i.p.) in mice. Ketamine presented a significant anxiogenic effect in the elevated plus-maze model of anxiety, also increasing locomotor activity. In the forced swimming and tail suspension tests, a significant decrease in immobility time after ketamine administration was observed. In addition to the behavioral changes induced by ketamine, this drug also increased lipid peroxidation, nitrite content and catalase activity, while decreased GSH levels in mice prefrontal cortex. In conclusion, our results confirm the antidepressant effects of ketamine, also showing a pro-oxidant effect of this drug.
Asunto(s)
Conducta Animal/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Ketamina/farmacología , Estrés Oxidativo/efectos de los fármacos , Análisis de Varianza , Animales , Catalasa/metabolismo , Relación Dosis-Respuesta a Droga , Conducta Exploratoria/efectos de los fármacos , Glutatión/metabolismo , Suspensión Trasera/métodos , Peroxidación de Lípido/efectos de los fármacos , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Nitritos/metabolismo , Estrés Oxidativo/fisiología , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/metabolismo , Natación/psicología , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismoRESUMEN
Oxidative stress (OS) has been related to cocaine's actions and also to numerous nervous system pathologies, including seizures. The purpose of this work was to determine the alterations in glutathione (GSH) content, nitrite/nitrate and MDA levels after cocaine-induced toxicity. Male Swiss mice were injected (i.p.) with cocaine 90 mg/kg and observed during 1h. After this cocaine overdose some animals presented status epilepticus (SE) while some died after seizures. These animals were divided in two groups, SE and death. A group with an association of the antioxidant Vitamin E (Vit E, 400mg/kg, i.p.) plus Coc 90 (Vit E plus Coc 90) was undertaken to assess the neuroprotective effect of Vit E. Neurochemical analyses were carried out in prefrontal cortex (PFC) and striatum (ST). GSH levels increased only after cocaine-induced death in both areas studied. Cocaine-induced SE has increased nitrite/nitrate content in PFC and ST, while after death the increase was only in PFC. MDA (the lipid peroxidation marker) was elevated after SE and death in ST and only after death in PFC. Antioxidant treatment significantly reduced the GSH, nitrite/nitrate in ST and MDA levels. Only nitrite/nitrate content in PFC has not been decreased by Vit E pretreatment. The results relate that oxidative stress occurs after cocaine-induced toxicity mainly after death indicating that probably the increase of OS in the animal's brain leads to seizures and death, also showing a protective effect of Vit E in this process. Together with previous results this study contributes to the knowledge of cocaine-induced toxicity and possible in the near future to the use of antioxidants in the prevention of cocaine-induced CNS toxicity.
Asunto(s)
Cocaína/toxicidad , Cuerpo Estriado/efectos de los fármacos , Muerte Súbita/etiología , Estrés Oxidativo/efectos de los fármacos , Corteza Prefrontal/efectos de los fármacos , Estado Epiléptico/inducido químicamente , Animales , Antioxidantes/metabolismo , Antioxidantes/farmacología , Biomarcadores/metabolismo , Trastornos Relacionados con Cocaína/complicaciones , Trastornos Relacionados con Cocaína/metabolismo , Trastornos Relacionados con Cocaína/fisiopatología , Cuerpo Estriado/patología , Cuerpo Estriado/fisiopatología , Modelos Animales de Enfermedad , Inhibidores de Captación de Dopamina/toxicidad , Glutatión/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Peroxidación de Lípido/fisiología , Masculino , Malondialdehído/metabolismo , Ratones , Nitratos/metabolismo , Nitritos/metabolismo , Estrés Oxidativo/fisiología , Corteza Prefrontal/patología , Corteza Prefrontal/fisiopatología , Estado Epiléptico/metabolismo , Estado Epiléptico/fisiopatología , Tocoferoles/metabolismo , Tocoferoles/farmacologíaRESUMEN
OBJECTIVES: Alpinia zerumbet, known in Brazil as colônia, is popularly used as a diuretic, antihypertensive, anti-ulcerogenic and sedative. Based on this, we have investigated the central effects of the essential oil isolated from A. zerumbet leaves. METHODS: Mice were treated once with 50 or 100 mg/kg of the essential oil, intraperitoneally, 30 min before being submitted to behavioural models of: locomotor activity (open-field), catalepsy, anxiety (elevated plus maze), depression (forced swimming test and tail suspension tests) as well as apomorphine-induced stereotypy. KEY FINDINGS: Results showed a dose-related decrease on locomotor activity and apomorphine-induced stereotypy. There was a decrease to the order of 55% of the grooming behaviour with both doses studied. The essential oil 100 mg/kg increased cataleptic activity (167%) and the immobility time in the forced swimming and tail suspension tests. Pretreatment with haloperidol (0.2 mg/kg, i.p.) alone also decreased locomotion, increased cataleptic activity and immobility time in the tail suspension test. No alterations in the elevated plus maze test were registered. CONCLUSIONS: The essential oil of A. zerumbet leaves had depressant and possible antipsychotic activity, since it could reverse the stereotypy induced by apomorphine, presenting effects comparable with those obtained with haloperidol treatment.
Asunto(s)
Alpinia/química , Conducta Animal/efectos de los fármacos , Sistema Nervioso Central/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Aceites Volátiles/farmacología , Extractos Vegetales/farmacología , Animales , Antipsicóticos/farmacología , Ansiedad , Apomorfina , Catalepsia , Depresores del Sistema Nervioso Central/farmacología , Antagonistas de Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Haloperidol/farmacología , Aprendizaje por Laberinto , Ratones , Aceites Volátiles/administración & dosificación , Aceites Volátiles/química , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Cola (estructura animal)RESUMEN
The present study investigated the effects of isopulegol, a monoterpene alcohol, in PTZ-induced convulsions and verified possible involved mechanisms. Saline, isopulegol or diazepam were intraperitonealy injected 30 min before PTZ. The latency for development of convulsions and mortality, as well as the mortality protection percentage was recorded. For investigating the involvement of GABAergic system, flumazenil was utilized. The activity of antioxidant enzyme catalase as well as the levels of reduced glutathione and lipid peroxidation were measured in brain hippocampus. Similarly to diazepam, isopulegol significantly prolonged the latency for convulsions and mortality of mice. All animals were protected against mortality at higher dose of isopulegol. Flumazenil pretreatment decreased the prolongation of seizure latency induced by both diazepam and isopulegol, although it was not able to reverse the latency and protection percent for mortality. Isopulegol also significantly prevented PTZ-induced increase in lipid peroxidation, preserved catalase activity in normal levels, and prevented the PTZ-induced loss of GSH in hippocampus of mice. These results suggest that the anticonvulsant and bioprotective effects of isopulegol against PTZ-induced convulsions are possibly related to positive modulation of benzodiazepine-sensitive GABA(A) receptors and to antioxidant properties.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Antioxidantes/uso terapéutico , Fitoterapia , Extractos Vegetales/uso terapéutico , Convulsiones/tratamiento farmacológico , Terpenos/uso terapéutico , Ácido gamma-Aminobutírico/metabolismo , Animales , Anticonvulsivantes/farmacología , Antioxidantes/farmacología , Catalasa/metabolismo , Monoterpenos Ciclohexánicos , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Flumazenil/farmacología , Glutatión/metabolismo , Hipocampo/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Masculino , Ratones , Pentilenotetrazol , Extractos Vegetales/farmacología , Receptores de GABA-A/metabolismo , Convulsiones/inducido químicamente , Convulsiones/mortalidad , Terpenos/aislamiento & purificación , Terpenos/farmacologíaRESUMEN
The present study investigated whether isopulegol, a monoterpene present in essential oils of several aromatic plants, would be able to promote some gastroprotective effect and also verified the possible mechanisms involved in this action. For this study, ethanol- and indomethacin-induced gastric ulcer models in mice and histopathological assessment were used. The roles of NO, sulfhydryls (glutathione, GSH), ATP-sensitive K(+) channels (K(ATP) channels), and prostaglandins were also investigated. Isopulegol exhibited a dose-related gastroprotective effect against ethanol-induced lesions, while the pretreatment with glibenclamide and indomethacin [but not with N(G)-nitro-L-arginine methyl ester] were able to reverse this action. The pretreatment with isopulegol also restored GSH levels to normal levels and exhibited dose-related gastroprotective effect against indomethacin-induced ulcer. The results suggested that isopulegol presents significant gastroprotective effects in both ethanol- and indomethacin-induced ulcer models, which appear to be mediated, at least in part, by endogenous prostaglandins, K(ATP) channel opening, and antioxidant properties.
Asunto(s)
Antioxidantes/farmacología , Úlcera Gástrica/prevención & control , Terpenos/farmacología , Animales , Antioxidantes/administración & dosificación , Monoterpenos Ciclohexánicos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Etanol/toxicidad , Glutatión/efectos de los fármacos , Glutatión/metabolismo , Indometacina/toxicidad , Canales KATP/metabolismo , Masculino , Ratones , Prostaglandinas/metabolismo , Úlcera Gástrica/inducido químicamente , Terpenos/administración & dosificaciónRESUMEN
O isopulegol é um monoterpeno álcool presente no óleo essencial de diversas plantas aromáticas, e tem sido utilizado na manufatura de perfumes com composições florais. No presente estudo, inicialmente, foi realizado um screenig farmacológico de ação central para a investigação de possíveis alterações comportamentais induzidas pelo isopulegol. Camundongos Swiss machos foram tratados com isopulegol (25 e 50 mg/kg) ou veículo (salina a 0,9% em Tween 0,3%) 30 (i.p.) ou 60 min (v.o.) antes dos experimentos. Flumazenil foi utilizado 15 min antes dos tratamentos com o intuito de investigar a participação dos receptores GABAA/BBZD nas ações do isopulegol. A concentração de monoaminas e seus metabólicos foi também verificada em corpo estriado após a administração aguda de isopulegol. Os resultados dos testes do LCE e hole board sugerem que o isopulegol apresenta provável efeito ansiolítico, o qual está relacionado, pelo menos em parte, a modulação positiva dos receptores GABAA/BZP. Esse efeito não acompanhado de ação sedativa em baixas doses, o que foi evidenciado pela ausência de diminuição de ALE no teste do campo aberto. Os parâmetros observados no teste do nado forçado, suspensão da cauda e tempo de sono induzido por pentobarbital sugere, que o isopulegol apresenta possível efeito depressor do SNC. Os efeitos centrais observados foram corroborados por uma redução na concentração de DA e NA, mas não de 5-HT. Com o objetivo de investigar o potencial anticonvulsivante do isopulegol, camundongos foram pré-tratados com isopulegol (25, 50, 100 e 200 mg/kg, i.p. ou v.o.) ou veículo antes de serem expostos ao modelo de convulsão induzida por PTZ (99 mg/kg, s.c.). A participação dos receptores GABAA/BZD (utilizando a administração prévia de flumazenil), bem como se uma possível atividade antioxidante estaria envolvida nas ações anticonvulsivantes do isopulegol, foram também investigadas...
Asunto(s)
Animales , Masculino , Ratones , Ansiedad , Depresión , ConvulsionesRESUMEN
Isopulegol is a monoterpene alcohol intermediate in the preparation of (-)-menthol and it is present in the essential oils of various plants. This work presents behavioral effects of isopulegol in animal models of open field, elevated plus maze (EPM), rota rod, hole board, barbiturate-induced sleeping time, tail suspension and forced swimming tests in mice. Isopulegol was administered intraperitoneally to male mice at single doses of 25 and 50 mg/kg, while diazepam 1 or 2 mg/kg and imipramine 10 or 30 mg/kg were used as standard drugs. The results showed that, similar to diazepam (1 mg/kg), both doses of isopulegol significantly modified all the observed parameters in the EPM test, without alter the general motor activity in the open field test. In the same way, both doses of isopulegol increased the number of head dips in the hole-board test. Forced swimming and tail suspension tests showed that isopulegol (25 and 50 mg/kg) was able to induce a significant increase in the immobility time, in opposite to imipramine, a recognized antidepressant drug. There was a decrease in the sleep latency time and prolongation of the pentobarbital-induced sleeping time with both doses of Isopulegol. Different from diazepam (2 mg/kg), isopulegol (25 e 50 mg/kg) had no effect on the motor coordination of animals in the rota rod test. These results showed that isopulegol presented depressant- and anxiolytic-like effects.
Asunto(s)
Ansiolíticos/farmacología , Depresores del Sistema Nervioso Central/farmacología , Terpenos/farmacología , Animales , Monoterpenos Ciclohexánicos , Suspensión Trasera , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , NataciónRESUMEN
In the present study were studied the antinociceptives properties of monoterpene R-(+)-limonene (LM) in chemical and thermal models of nociception in mice. The R-(+)-limonene was administered, intraperitoneally (i.p.), at doses of 25 and 50 mg/kg. The results showed significant inhibition produced on chemical nociception induced by intraperitoneal acetic-acid and in the second phase of subplantar formalin test, but did not manifest a significant effect in hot-plate test. The R-(+)-limonene-induced antinociception in second phase of formalin test was insensitive to naloxone (1 mg/kg, s.c.). It was also demonstrated that R-(+)-limonene (25, 50 mg/kg) neither significantly enhanced the pentobarbital-sleeping time nor impaired the motor performance in rota-rod test, indicating that the observed antinociception is unlikely to be due to sedation or motor abnormality. In conclusion it may be suggested that the R-(+)-limonene presented antinociceptive activity and that, probably, this action can be related with peripheral analgesia, but, not with the stimulation of opioids receptors.